MCID: ANC002
MIFTS: 47

Anca-Associated Vasculitis

Categories: Rare diseases

Aliases & Classifications for Anca-Associated Vasculitis

MalaCards integrated aliases for Anca-Associated Vasculitis:

Name: Anca-Associated Vasculitis 54
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 54 74
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis 54
Aav 54

Classifications:



External Ids:

UMLS 74 C2717865

Summaries for Anca-Associated Vasculitis

NIH Rare Diseases : 54 Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of diseases (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis), characterized by destruction and inflammation of small vessels. The clinical signs vary and affect several organs, such as the kidney, stomach, intestine, and lung. Skin lesions, such as purpura and urticaria, result when blood from small vessels leaks under the skin. AAV occurs when neutrophils attack small and medium vessels of the body. The underlying reason for this remains unclear. Treatment includes cyclophosphamide,  glucocorticoids and other autoimmune drugs such as rituximab. 

MalaCards based summary : Anca-Associated Vasculitis, also known as anti-neutrophil cytoplasmic antibody-associated vasculitis, is related to vasculitis and rapidly progressive glomerulonephritis. An important gene associated with Anca-Associated Vasculitis is MPO (Myeloperoxidase), and among its related pathways/superpathways are Innate Immune System and Allograft rejection. The drugs alemtuzumab and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, lung and kidney.

Wikipedia : 77 Granulomatosis with polyangiitis (GPA), formerly known as Wegener''s granulomatosis (WG), is a long-term... more...

Related Diseases for Anca-Associated Vasculitis

Diseases related to Anca-Associated Vasculitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 429)
# Related Disease Score Top Affiliating Genes
1 vasculitis 31.8 MPO PRTN3 SERPINA1 TNF
2 rapidly progressive glomerulonephritis 30.6 MPO PRTN3
3 granulocytopenia 30.4 MPO TNF
4 polyarteritis nodosa 30.3 IL6 MPO PRTN3
5 arthritis 30.3 HLA-DRB1 IL6 TNF
6 otitis media 30.0 IL6 TLR2 TNF
7 ischemic heart disease 29.8 IL6 TNF
8 microscopic polyangiitis 29.8 HLA-DRB1 MPO TNF
9 autoimmune disease 29.7 CTLA4 HLA-DRB1 IL6 TNF
10 bronchiectasis 29.7 MPO SERPINA1 TLR2
11 mixed connective tissue disease 29.6 HLA-DRB1 IL6 TNF
12 connective tissue disease 29.6 HLA-DRB1 IL6 TNF
13 aplastic anemia 29.6 HLA-DRB1 IL6 TNF
14 pneumonia 29.5 IL6 MPO TLR2 TNF
15 ulcerative colitis 29.5 IL6 MPO PRTN3 TNF
16 colitis 29.4 CTLA4 IL6 MPO TNF
17 meningitis 29.4 IL6 TLR2 TNF
18 granulomatosis with polyangiitis 29.1 CTLA4 HMGB1 MPO PRTN3 SERPINA1 TLR2
19 inflammatory bowel disease 29.1 IL6 MPO TLR2 TNF
20 periodontitis 29.0 IL6 TLR2 TNF
21 cholangitis 29.0 HLA-DRB1 IL6 PRTN3 TNF
22 common variable immunodeficiency 29.0 CTLA4 IL6 TLR2 TNF
23 liver disease 28.9 IL6 SERPINA1 TNF
24 lung disease 28.8 IL6 MPO PRTN3 SERPINA1 TLR2 TNF
25 rheumatoid arthritis 28.6 CTLA4 HLA-DRB1 HMGB1 IL6 PRTN3 TLR2
26 systemic lupus erythematosus 28.3 CTLA4 HLA-DRB1 HMGB1 IL6 MPO PRTN3
27 glomerulonephritis 10.5
28 epileptic encephalopathy, childhood-onset 10.4 MPO PRTN3
29 arteritic anterior ischemic optic neuropathy 10.4 MPO PRTN3
30 aortitis 10.3
31 monoclonal paraproteinemia 10.3 MPO PRTN3
32 influenza 10.3
33 lupus erythematosus 10.3
34 hemophilia b 10.3
35 muscular dystrophy 10.3
36 kawasaki disease 10.3
37 proliferative glomerulonephritis 10.3 IL6 MPO
38 chronic orbital inflammation 10.3 CTLA4 PRTN3
39 scleroderma, familial progressive 10.2
40 triiodothyronine receptor auxiliary protein 10.2
41 pulmonary fibrosis 10.2
42 systemic scleroderma 10.2
43 asbestosis 10.2 IL6 SERPINA1
44 chronic maxillary sinusitis 10.2 MPO PRTN3
45 anterior scleritis 10.2 MPO PRTN3
46 proctitis 10.2 MPO TNF
47 autoimmune pancreatitis 10.2 CTLA4 HLA-DRB1
48 muscular dystrophy, duchenne type 10.2
49 glycogen storage disease 10.2
50 retinal degeneration 10.2

Graphical network of the top 20 diseases related to Anca-Associated Vasculitis:



Diseases related to Anca-Associated Vasculitis

Symptoms & Phenotypes for Anca-Associated Vasculitis

Drugs & Therapeutics for Anca-Associated Vasculitis

Drugs for Anca-Associated Vasculitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
alemtuzumab Approved, Investigational Phase 4 216503-57-0
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
3
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 446-86-6 2265
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
5
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 302-25-0
6
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Not Applicable 2921-57-5
7
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
9
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
10
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
11
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
12
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
14
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3,Not Applicable 2920-86-7
15 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
19 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Not Applicable
21 Alkylating Agents Phase 4,Phase 3,Phase 2,Not Applicable
22 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
24 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
25 Methylprednisolone Acetate Phase 4,Phase 2,Phase 3,Not Applicable
26 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
27 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
29 Hormones Phase 4,Phase 2,Phase 3,Not Applicable
30 Prednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
31 Protective Agents Phase 4,Phase 2,Phase 3,Not Applicable
32 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
33 Folate Phase 4,Phase 3,Phase 2,Phase 1
34 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
35 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
36 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
38 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1
40 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
41 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Not Applicable
43 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Antiemetics Phase 4,Phase 2,Phase 3,Not Applicable
45 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
46 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Not Applicable
47 Antibodies Phase 4,Phase 2,Phase 3,Not Applicable
48 Antibodies, Antineutrophil Cytoplasmic Phase 4,Phase 3,Phase 2,Not Applicable
49 Immunoglobulins Phase 4,Phase 2,Phase 3,Not Applicable
50 Tin Fluorides Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 126)
# Name Status NCT ID Phase Drugs
1 Alemtuzumab for ANCA Associated Refractory Vasculitis Unknown status NCT01405807 Phase 4 Alemtuzumab
2 CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors Unknown status NCT00399399 Phase 4 azathioprine;cyclophosphamide
3 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
4 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
5 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
6 Low-dose Glucocorticoid Vasculitis Induction Study Recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
7 Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Recruiting NCT02749292 Phase 4 Rituximab
8 A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis Recruiting NCT02115997 Phase 4 Methylprednisolone;Prednisone;Rituximab
9 Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Recruiting NCT03164473 Phase 4 Rituximab;Azathioprine;Placebo-rituximab;Placebo-azathioprine
10 Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Terminated NCT00128895 Phase 4 azathioprine
11 Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Terminated NCT02626845 Phase 4 Rituximab
12 Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Terminated NCT00747461 Phase 4
13 WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
14 Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA) Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
15 Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery Unknown status NCT01297959 Phase 3 E-101 Solution 300 GU/ml;Saline solution
16 Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
17 Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
18 Efficacy Study of Two Treatments in the Remission of Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
19 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
20 Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis Completed NCT00414128 Phase 2, Phase 3 mycophenolate mofetil;cyclophosphamide
21 Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis Completed NCT00987389 Phase 3 Glucocorticoids
22 Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis (PEXIVAS) - Glucocorticoids Completed NCT03919825 Phase 3 Glucocorticoids - Standard Dose;Glucocorticoids - Reduced Dose
23 A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis Completed NCT02020889 Phase 3 Placebo
24 Belimumab in Remission of VASculitis Completed NCT01663623 Phase 3 Azathioprine
25 Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
26 Etanercept for Wegener's Granulomatosis Completed NCT00005007 Phase 2, Phase 3 Etanercept
27 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
28 Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis Recruiting NCT03942887 Phase 3 Rituximab;endoxan;Methylprednisolone;Prednisolone
29 Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease Recruiting NCT03323476 Phase 3 Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
30 Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) Recruiting NCT02108860 Phase 3 Abatacept;placebo
31 The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach Recruiting NCT01933724 Phase 3 5 mg prednisone;0 mg prednisone
32 The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach Recruiting NCT01940094 Phase 3 5 mg Prednisone;0 mg Prednisone
33 Rituximab in Eosinophilic Granulomatosis With Polyangiitis Recruiting NCT02807103 Phase 3 Rituximab;Placebo-rituximab;Cyclophosphamide;Placebo-cyclophosphamide
34 A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Active, not recruiting NCT02994927 Phase 3 CCX168;Prednisone;Cyclophosphamide;Azathioprine
35 Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab Active, not recruiting NCT02433522 Phase 3 rituximab;Placebo
36 Rituximab Vasculitis Maintenance Study Active, not recruiting NCT01697267 Phase 3 Azathioprine
37 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Active, not recruiting NCT03298061 Phase 3 Mepolizumab;Prednisolone
38 The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children Not yet recruiting NCT03692416 Phase 3 Ibuprofen;Prednisone;Methotrexate
39 Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis Not yet recruiting NCT03920722 Phase 3 Rituximab;placebo
40 IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis Terminated NCT00307645 Phase 3 Cyclophosphamide;Mycophenolate mofetil;Azathioprine;Prednisone (and methylprednisolone)
41 Intravenous Immunoglobulin After Relapse in Vasculitis Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
42 Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis Terminated NCT01446211 Phase 3 Gusperimus + glucocorticoids;cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
43 Plasma Exchange for Renal Vasculitis Terminated NCT01408836 Phase 2, Phase 3 Intravenous methyl prednisolone;Methyl prednisolone
44 CMV Modulation of the Immune System in ANCA-associated Vasculitis Unknown status NCT01633476 Phase 2 Valaciclovir
45 Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study Unknown status NCT03010436 Phase 2 Benralizumab
46 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
47 Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis Completed NCT02222155 Phase 2 CCX168 low dose plus standard of care;CCX168 high dose plus standard of care
48 A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis Completed NCT01363388 Phase 2 Placebo;CCX168
49 Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis Completed NCT00293072 Phase 2 Rituximab
50 Anti-Cytokine Therapy for Vasculitis Completed NCT00753103 Phase 2 Cyclophosphamide;Prednisolone;Azathioprine;Mycophenolate mofetil;Methylprednisolone

Search NIH Clinical Center for Anca-Associated Vasculitis

Genetic Tests for Anca-Associated Vasculitis

Anatomical Context for Anca-Associated Vasculitis

MalaCards organs/tissues related to Anca-Associated Vasculitis:

42
Neutrophil, Lung, Kidney, Heart, Eye, Skin, B Cells

Publications for Anca-Associated Vasculitis

Articles related to Anca-Associated Vasculitis:

(show top 50) (show all 819)
# Title Authors Year
1
Clinical impact of alpha-1-antitrypsin deficiency in ANCA-associated vasculitis: results from a French retrospective monocentric cohort of 142 consecutive patients. ( 30824651 )
2019
2
MYCYC: unravelling the long road ahead in ANCA-associated vasculitis. ( 30894345 )
2019
3
Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis. ( 30896460 )
2019
4
Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Causes Aortic Valve Degeneration and Severe Aortic Regurgitation. ( 30930460 )
2019
5
Pharmaceutical immunoglobulins reduce neutrophil extracellular trap formation and ameliorate the development of MPO-ANCA-associated vasculitis. ( 30932727 )
2019
6
PR3-ANCA-associated vasculitis is associated with a specific motif in the peptide-binding cleft of HLA-DP molecules. ( 30938436 )
2019
7
A Case of ANCA-Associated Vasculitis. ( 30952628 )
2019
8
Rapid progression to end-stage renal disease in a young female with mixed immunopathological features of lupus and ANCA-associated vasculitis. ( 30968562 )
2019
9
Occurrence of cerebral small vessel disease at diagnosis of MPO-ANCA-associated vasculitis. ( 30982149 )
2019
10
Estimating the Change in Renal Function During the First Year of Therapy in ANCA-Associated Vasculitis. ( 30993234 )
2019
11
No Difference in Cognitive Dysfunction Among Patients with ANCA-Associated Vasculitis, Rheumatoid Arthritis or Chronic Kidney Disease. ( 31030697 )
2019
12
Plasma exchange is highly effective for ANCA-associated vasculitis patients with rapidly progressive glomerulonephritis who have advanced to dialysis dependence: A single-center case series. ( 31033151 )
2019
13
Comparison of the birmingham vasculitis activity score and the five factors score to assess survival in anca-associated vasculitis. ( 31033198 )
2019
14
Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. ( 31049594 )
2019
15
Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series. ( 31088509 )
2019
16
ANCA-Associated Vasculitis in Inflammatory Bowel Disease. ( 31093814 )
2019
17
Glucocorticoid-free induction regimen in severe ANCA-associated vasculitis using a combination of rituximab and eculizumab. ( 31102526 )
2019
18
The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis. ( 29885746 )
2019
19
Myeloperoxidase-ANCA-positive granulomatosis with polyangiitis is a distinct subset of ANCA-associated vasculitis: A retrospective analysis of 455 patients from a single center in China. ( 29887327 )
2019
20
Systematic review and meta-analysis for 2017 clinical practice guidelines of the Japan research committee of the ministry of health, labour, and welfare for intractable vasculitis for the management of ANCA-associated vasculitis. ( 29996690 )
2019
21
2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis. ( 30001655 )
2019
22
The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature. ( 30074077 )
2019
23
ANCA associated vasculitis: experience of a tertiary care referral center. ( 30095143 )
2019
24
Low serum complement 3 level is associated with severe ANCA-associated vasculitis at diagnosis. ( 30168048 )
2019
25
Targeted immunotherapy strategies in ANCA-associated vasculitis. ( 30201478 )
2019
26
Utility of neutrophil CD64 and serum TREM-1 in distinguishing bacterial infection from disease flare in SLE and ANCA-associated vasculitis. ( 30446886 )
2019
27
Clinical and histopathological prognostic factors affecting the renal outcomes in childhood ANCA-associated vasculitis. ( 30607566 )
2019
28
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. ( 30612116 )
2019
29
Hypertrophic pachymeningitis and cerebral venous thrombosis in myeloperoxidase-ANCA associated vasculitis. ( 30635307 )
2019
30
Author Correction: Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. ( 30655606 )
2019
31
Low-dose rituximab as induction therapy for ANCA-associated vasculitis. ( 30680533 )
2019
32
Updating OMERACT Core Set of Domains for ANCA-Associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability and Health. ( 30709951 )
2019
33
Prognostic nutritional index is associated with disease severity and relapse in ANCA-associated vasculitis. ( 30729693 )
2019
34
Consideration concerning similarities and differences between ANCA-associated vasculitis and IgG-4-related diseases: case series and review of literature. ( 30734199 )
2019
35
Changing landscape of immunosuppression in ANCA-associated vasculitis. ( 30755415 )
2019
36
Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort. ( 30767717 )
2019
37
Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study. ( 30777023 )
2019
38
Persistent antiphospholipid antibodies are associated with thrombotic events in ANCA-associated vasculitis: A retrospective monocentric study. ( 30798998 )
2019
39
Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification. ( 30805643 )
2019
40
Diffuse alveolar hemorrhage in a patient with ANCA-associated vasculitis after thyroidectomy: A case report. ( 30813199 )
2019
41
Immunoglobulins G from patients with ANCA-associated vasculitis are atypically glycosylated in both the Fc and Fab regions and the relation to disease activity. ( 30818380 )
2019
42
Testicular granulomatous vasculitis mimicking testicular torsion in an anti-neutrophil cytoplasmic antibody-associated vasculitis patient. ( 30719308 )
2019
43
Platelets release proinflammatory microparticles in anti-neutrophil cytoplasmic antibody-associated vasculitis. ( 30843591 )
2019
44
Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis. ( 30886997 )
2019
45
Response to: 'MYCYC, unravelling the long road ahead in ANCA-associated vasculitis' by Jain et al. ( 30894344 )
2019
46
Erratum: Azathioprine hypersensitivity syndrome in anti-myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis. ( 30976415 )
2019
47
A case report dysregulated neutrophil extracellular traps in a patient with propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. ( 31027105 )
2019
48
Efficacy of Plasma Exchange in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis. ( 31033197 )
2019
49
Epidemiology and clinical features of childhood-onset anti-neutrophil cytoplasmic antibody-associated vasculitis: a clinicopathological analysis. ( 31076873 )
2019
50
Citrullinated histone H3 expression in anti-neutrophil cytoplasmic antibody-associated vasculitis in older Japanese autopsy patients. ( 30623538 )
2019

Variations for Anca-Associated Vasculitis

Expression for Anca-Associated Vasculitis

Search GEO for disease gene expression data for Anca-Associated Vasculitis.

Pathways for Anca-Associated Vasculitis

Pathways related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.4 CTLA4 HLA-DRB1 HMGB1 IL6 MPO PRTN3
2
Show member pathways
12.66 CTLA4 HLA-DRB1 IL6 TNF
3
Show member pathways
12.38 CTLA4 IL6 TNF
4
Show member pathways
12.33 HLA-DRB1 IL6 TLR2 TNF
5 12.29 CTLA4 MPO TLR2 TNF
6 12.18 HLA-DRB1 IL6 TNF
7
Show member pathways
12.15 IL6 MPO TNF
8
Show member pathways
12.14 IL6 TLR2 TNF
9
Show member pathways
12.07 IL6 TLR2 TNF
10
Show member pathways
12.06 HLA-DRB1 TLR2 TNF
11
Show member pathways
12.02 IL6 TLR2 TNF
12
Show member pathways
11.98 IL6 TLR2 TNF
13 11.98 IL6 TLR2 TNF
14 11.93 HLA-DRB1 MPO TLR2
15 11.92 HLA-DRB1 IL6 TLR2 TNF
16
Show member pathways
11.84 IL6 TLR2 TNF
17 11.78 IL6 MPO TNF
18 11.69 HLA-DRB1 IL6 TNF
19 11.67 IL6 TLR2 TNF
20
Show member pathways
11.66 HMGB1 IL6 TLR2 TNF
21 11.43 IL6 SERPINA1 TNF
22 11.35 IL6 TLR2 TNF
23 11.27 IL6 TLR2 TNF
24 11.22 IL6 TNF
25 11.19 IL6 TNF
26 11.15 IL6 TNF
27 11.13 IL6 TNF
28 11.09 HMGB1 MPO
29 10.98 CTLA4 HLA-DRB1 IL6 TLR2 TNF
30 10.96 HLA-DRB1 IL6 TNF
31 10.95 IL6 TNF
32 10.94 HMGB1 IL6 MPO TNF
33 10.85 IL6 TNF
34 10.76 MPO TNF

GO Terms for Anca-Associated Vasculitis

Cellular components related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.63 HMGB1 IL6 MPO PRTN3 SERPINA1 TNF
2 membrane raft GO:0045121 9.43 PRTN3 TLR2 TNF
3 cell surface GO:0009986 9.26 HLA-DRB1 HMGB1 TLR2 TNF
4 extracellular space GO:0005615 9.1 HMGB1 IL6 MPO PRTN3 SERPINA1 TNF

Biological processes related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.88 CTLA4 HLA-DRB1 HMGB1 TLR2
2 inflammatory response GO:0006954 9.8 HMGB1 IL6 TLR2 TNF
3 positive regulation of apoptotic process GO:0043065 9.73 CTLA4 HMGB1 IL6 TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.72 IL6 TLR2 TNF
5 defense response to Gram-positive bacterium GO:0050830 9.65 IL6 TLR2 TNF
6 immune response GO:0006955 9.65 CTLA4 HLA-DRB1 IL6 TLR2 TNF
7 toll-like receptor signaling pathway GO:0002224 9.63 HMGB1 TLR2
8 acute-phase response GO:0006953 9.63 IL6 SERPINA1
9 lipopolysaccharide-mediated signaling pathway GO:0031663 9.62 TLR2 TNF
10 negative regulation of interferon-gamma production GO:0032689 9.62 HLA-DRB1 HMGB1
11 positive regulation of interleukin-8 production GO:0032757 9.61 TLR2 TNF
12 negative regulation of neurogenesis GO:0050768 9.6 IL6 TNF
13 positive regulation of interleukin-12 production GO:0032735 9.59 HMGB1 TLR2
14 positive regulation of interleukin-10 production GO:0032733 9.58 HMGB1 TLR2
15 microglial cell activation GO:0001774 9.57 TLR2 TNF
16 positive regulation of glial cell proliferation GO:0060252 9.56 IL6 TNF
17 neutrophil degranulation GO:0043312 9.55 HMGB1 MPO PRTN3 SERPINA1 TLR2
18 negative regulation of growth of symbiont in host GO:0044130 9.54 MPO TNF
19 negative regulation of phagocytosis GO:0050765 9.52 PRTN3 TLR2
20 inflammatory response to antigenic stimulus GO:0002437 9.51 HLA-DRB1 HMGB1
21 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.5 HMGB1 TLR2 TNF
22 negative regulation of lipid storage GO:0010888 9.46 IL6 TNF
23 positive regulation of neuroinflammatory response GO:0150078 9.4 IL6 TNF
24 response to glucocorticoid GO:0051384 9.37 IL6 TNF
25 positive regulation of interferon-beta production GO:0032728 9.3 TLR2
26 positive regulation of chemokine production GO:0032722 9.13 IL6 TLR2 TNF
27 positive regulation of interleukin-6 production GO:0032755 8.92 HMGB1 IL6 TLR2 TNF

Molecular functions related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopolysaccharide binding GO:0001530 8.96 HMGB1 TLR2
2 cytokine activity GO:0005125 8.8 HMGB1 IL6 TNF

Sources for Anca-Associated Vasculitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....